Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: JT who wrote (20732)	5/14/1998 6:53:00 AM
From: Henry Niman	Respond to of 32384

JT, I didn't hear the teaser, but someone on a breast cancer listserver indicated that Dennis Slamon would be on CBS's Good Morning America? today. He is involved in the development of GNE's Herceptin, which is a monoclonal antibody that targets HER2 on the surface of breast cancers (it is over expressed on a subset that frequently have a poorer prognosis). Since it may be approved soon, several news outlets may be running stories. Of interest to LGND shareholders is the fact that DAB389-EGF is a fusion protein that targets EGF which is also called HER1 and it is closely related to HER2 (HER stands for Human EGF Receptor). DAB389-EGF is in phase I studies against a variety of cancer which I believe includes breast cancer (some of which over express EGF). Details at home.att.net